Merck KGaA receives global marketing and commercialization rights to Genea Biomedx’s product portfolio

Merck Serono S.A., a biopharmaceutical company and subsidiary ofMerck KgaA, has entered into a global agreement with Genea Biomedx UK Ltd., an IVF technology company, to advance fertility science and helping couples create families.

Under the agreement, Merck KGaA receives global marketing and commercialization rights to Genea Biomedx’s product portfolio. With the global rights to these three product lines and future developments, Merck KGaA is expanding its market position, offering key potentially outcome improving technologies to support standardization, automation and objectivity.

To further strengthen this position, Merck KGaA will closely collaborate with Genea Biomedx to jointly develop other innovative technology products and services, and have formed a development hub to pave the way for further improvements for the patient. The collaboration is effective from May 1, 2015.

Genea Biomedx and Merck Serono will commercialize and marketGenea’s key fertility products: Gavi, Geri and Gems. The partners will jointly work on other innovations and technologies, and will create centres of excellence in Europe and Asia. This agreement enablesMerck Serono and Genea Biomedx to develop fertility technologies to create and deliver innovative solutions to Assisted Reproductive Treatment (ART) clinics and, in turn, better outcomes for patients.